VYNE
Price:
$2.5
Market Cap:
$36.88M
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo...[Read more]
Industry
Biotechnology
IPO Date
2018-01-25
Stock Exchange
NASDAQ
Ticker
VYNE
According to VYNE Therapeutics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 20.73M. This represents a change of -69.32% compared to the average of 67.57M of the last 4 quarters.
The mean historical Enterprise Value of VYNE Therapeutics Inc. over the last ten years is 169.62M. The current 20.73M Enterprise Value has changed 1.12% with respect to the historical average. Over the past ten years (40 quarters), VYNE's Enterprise Value was at its highest in in the March 2018 quarter at 582.25M. The Enterprise Value was at its lowest in in the December 2022 quarter at -23197564.80.
Average
169.62M
Median
127.40M
Minimum
-22654870.20
Maximum
581.07M
Discovering the peaks and valleys of VYNE Therapeutics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 220.39%
Maximum Annual Enterprise Value = 581.07M
Minimum Annual Increase = -313.93%
Minimum Annual Enterprise Value = -22654870.20
Year | Enterprise Value | Change |
---|---|---|
2023 | -6469910.00 | -71.44% |
2022 | -22654870.20 | -313.93% |
2021 | 10.59M | -94.18% |
2020 | 182.10M | 42.93% |
2019 | 127.40M | 220.39% |
2018 | 39.76M | -93.16% |
2017 | 581.07M | 77.55% |
2016 | 327.26M | 13.84% |
The current Enterprise Value of VYNE Therapeutics Inc. (VYNE) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-6178320.83
5-year avg
58.19M
10-year avg
169.62M
VYNE Therapeutics Inc.’s Enterprise Value is greater than Akari Therapeutics, Plc (11.15M), greater than Salarius Pharmaceuticals, Inc. (-721382.00), greater than Axcella Health Inc. (-14986000.00), greater than Magenta Therapeutics, Inc. (-114170976.00), greater than Histogen Inc. (-4487565.00), greater than First Wave BioPharma, Inc. (2.79M), less than SAB Biotherapeutics, Inc. (38.27M), greater than Vaccinex, Inc. (927.06K), greater than GeoVax Labs, Inc. (13.02M), less than Catalyst Biosciences, Inc. (941.99M), less than Unicycive Therapeutics, Inc. (39.46M), greater than Pulmatrix, Inc. (11.13M), less than Cidara Therapeutics, Inc. (40.18M), greater than Phio Pharmaceuticals Corp. (-3532813.00), greater than Kronos Bio, Inc. (8.63M), less than Veracyte, Inc. (2.91B), greater than Atreca, Inc. (-8620212.00), greater than Longeveron Inc. (3.30M), less than Lyra Therapeutics, Inc. (23.31M), greater than Revelation Biosciences, Inc. (-4075884.00), greater than Zura Bio Limited (-39351752.00), greater than ZyVersa Therapeutics, Inc. (2.55M), greater than TransCode Therapeutics, Inc. (894.46K),
Company | Enterprise Value | Market cap |
---|---|---|
11.15M | $12.40M | |
-721382.00 | $2.23M | |
-14986000.00 | $0 | |
-114170976.00 | $42.44M | |
-4487565.00 | $85.44K | |
2.79M | $5.99M | |
38.27M | $42.92M | |
927.06K | $3.77M | |
13.02M | $21.61M | |
941.99M | $19.42M | |
39.46M | $71.00M | |
11.13M | $21.91M | |
40.18M | $163.62M | |
-3532813.00 | $1.86M | |
8.63M | $57.80M | |
2.91B | $3.17B | |
-8620212.00 | $3.57M | |
3.30M | $24.48M | |
23.31M | $11.78M | |
-4075884.00 | $2.47M | |
-39351752.00 | $148.87M | |
2.55M | $2.67M | |
894.46K | $2.62M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like VYNE Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like VYNE Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is VYNE Therapeutics Inc.'s Enterprise Value?
What is the highest Enterprise Value for VYNE Therapeutics Inc. (VYNE)?
What is the 3-year average Enterprise Value for VYNE Therapeutics Inc. (VYNE)?
What is the 5-year average Enterprise Value for VYNE Therapeutics Inc. (VYNE)?
How does the current Enterprise Value for VYNE Therapeutics Inc. (VYNE) compare to its historical average?